^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TP53 mutation + ZFHX3 mutation

    i
    Other names: ZFHX3, Zinc Finger Homeobox 3, AT-Binding Transcription Factor 1, Zinc Finger Homeodomain Protein, Zinc Finger Homeobox Protein, AT Motif-Binding Factor 1, ATBF1, ZFH-3, Alpha-Fetoprotein Enhancer Binding Protein, Alpha-Fetoprotein Enhancer-Binding Protein, Chromosome 16 Open Reading Frame 47, C16orf47, ZNF927, ATBT, TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
    Entrez ID:
    7157; 463
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    almost3years
    Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors. (PubMed, Scand J Immunol)
    Coexisting TP53 and ZFHX3 mutations are independent prognostic factors for advanced-stage NSCLC patients undergoing ICI treatment. These findings could help identify patients harboring TP53 mutations that would benefit from ICI treatment.
    Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ZFHX3 (Zinc Finger Homeobox 3)
    |
    TP53 mutation • TP53 wild-type • TP53 mutation + ZFHX3 mutation • ZFHX3 mutation